ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Also in this 12-page issue: ASCO urges freeze of Medicare payments for chemotherapy at 2004 levels for next two years.

February 20, 2004

Test May Identify Predictors For Recurrence Post-Surgery

January 28, 2011

Duke Officials Decline To Provide Details Of Probe

July 23, 2010

Ethics Commission To Continue Consideration Of Compensation For Injured Research Subjects

June 20, 1980

ORI Finds Misconduct By CIT Professor

August 4, 1995

NCI To Broaden Support, Especially For Staff, Through Core Grants to Comprehensive Centers

November 21, 1975